Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cantargia AB ( (SE:CANTA) ) has provided an announcement.
Cantargia AB has released its interim report for January to March 2026, outlining operational progress across its pipeline of targeted antibody-based drug candidates. The report highlights developments in key programs such as nadunolimab, CAN14, CANxx and the CAN10 strategic partnership, which collectively underscore the company’s efforts to advance novel therapies for severe diseases and maintain engagement with international investors through translated financial disclosures.
The most recent analyst rating on (SE:CANTA) stock is a Buy with a SEK14.00 price target. To see the full list of analyst forecasts on Cantargia AB stock, see the SE:CANTA Stock Forecast page.
More about Cantargia AB
Cantargia AB is a Swedish biotechnology company focused on developing targeted antibody-based drugs for cancer, immunological and other life-threatening diseases. Its drug candidates aim to provide new and improved treatments for serious and debilitating conditions, positioning the company within the innovative therapeutics segment of the biopharmaceutical industry.
Average Trading Volume: 1,703,446
Technical Sentiment Signal: Sell
Current Market Cap: SEK852.7M
See more data about CANTA stock on TipRanks’ Stock Analysis page.